Rrx-001
Brain Tumor, Pediatric
EpicentRx, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Brain Tumor, Pediatric cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ezobresib Dana-Farber Cancer Institute | Phase 1 | CC |
BMS-986378 Dana-Farber Cancer Institute | Phase 1 | CC |
Same molecule, other indications
Rrx-001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →